Activated Charcoal Antimony Arsenate Bryonia Alba
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
多成分製劑 (Multi-Component Preparation): 評估報告
One-Sentence Summary
This submission contains a complex multi-component preparation composed of 21 heterogeneous ingredients—including herbal extracts, minerals, microorganisms, and gases—that does not match any single registered pharmaceutical entity. The TxGNN model was unable to generate repurposing predictions for this compound due to the absence of a DrugBank identifier and the non-standard nature of the formulation. There is currently no clinical trial evidence, no supporting literature, and no regulatory authorization in any examined market.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory registration found) |
| Predicted New Indication | None — TxGNN pipeline returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies, no registration) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN repurposing prediction was generated for this submission. The pipeline requires a valid DrugBank ID (drugbank_id: null) to anchor the compound within the knowledge graph; without it, neither knowledge-graph traversal nor deep-learning scoring could be performed.
The submitted “INN” field is not a single international nonproprietary name but a concatenated list of 21 discrete substances spanning at least five pharmacological categories: adsorption agents (activated charcoal), inorganic minerals (copper, tin, phosphorus, potassium chloride), botanical extracts (Bryonia alba, Chelidonium majus, Gelsemium sempervirens, Ipecac, Polygala senega, Pratia purpurascens, Veratrum viride), biological/microbial antigens (Haemophilus influenzae type B, Mycoplasma pneumoniae, Streptococcus pneumoniae), and other materials (camphor, oxygen, quinine hydrochloride, antimony arsenate, Sus scrofa lung). The combination profile is consistent with a homeopathic or naturopathic complex remedy, for which standard pharmacokinetic and mechanistic data are generally unavailable.
Without an established mechanism of action, a registered indication, or a drug-disease relationship node in the TxGNN knowledge graph, the repurposing hypothesis cannot be mechanistically justified at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No regulatory authorizations were found. This preparation is not registered in Taiwan; US NDA/ANDA records were not queried separately due to the absence of a standard drug identifier.
Safety Considerations
Please refer to the package insert for safety information.
Note: Because the formulation includes several potentially bioactive components—including quinine hydrochloride (risk of QT prolongation and cinchonism), camphor (risk of seizures at high doses), ipecac (emetogenic, cardiotoxic at high doses), and antimony arsenate (heavy metal toxicity)—a full ingredient-level safety review is strongly recommended before any clinical or research application is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: This submission cannot be meaningfully evaluated by the TxGNN drug repurposing pipeline because the input does not correspond to a single, identifiable pharmaceutical entity—it is a multi-ingredient mixture lacking a DrugBank ID, a registered indication, or any retrievable mechanistic profile. No repurposing prediction was produced, and no supporting evidence exists.
To proceed, the following is needed:
- Clarify the submission intent: Determine whether this is a homeopathic complex, a compounded formulation, a research mixture, or a data entry error that concatenated multiple drug names into a single record.
- Decompose the formulation: If repurposing analysis is desired, each bioactive component (e.g., quinine, activated charcoal, ipecac) should be submitted individually as a separate Evidence Pack with its own INN and DrugBank ID.
- Obtain regulatory documentation: If the combination product is registered in any jurisdiction, retrieve the package insert or product monograph to establish the approved indication and safety profile.
- Resolve DrugBank mapping: Run each ingredient through the DrugBank normalization pipeline (
drugbank_mapper.py) to obtain valid identifiers before re-submitting to TxGNN. - Address data gaps DG001 and DG002: Retrieve TFDA package insert warnings/contraindications and mechanism of action data for each identifiable component.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.